论文部分内容阅读
欧洲多中心进行了尼莫地平与安慰剂对照随机抽样双盲临床试验以估价尼莫地平在急性大脑中动脉(MCA)卒中的疗效。尼莫地平口服剂量每次30mg,每天4次服用21天,与安慰剂对照。在开始治疗后的3个月进行追踪。 病人选择与入院时MCA范围缺血性卒中临床诊断相符的有症状和体征的男、女病人。标准:(1)卒中的发生是治疗开始前的48h内;(2)年龄范围40～80岁(含80岁);(3)神经和功能缺陷由轻到重(神经评分≤50和Barthel指数≤60)。MCA皮层与皮层下任何大小的缺血性梗塞,符合临床特点均得经CT扫描证实。
A multicenter European randomized, double-blind, nimodipine-placebo trial evaluated the efficacy of nimodipine in the treatment of acute middle cerebral artery (MCA) stroke. Nimodipine oral dose of 30mg, 4 times a day for 21 days, compared with placebo. Follow up 3 months after starting treatment. Patient selection Male and female patients with symptomatic and physical signs corresponding to the clinical diagnosis of MCA-range ischemic stroke at admission. Criteria: (1) Stroke occurred within 48 hours prior to initiation of treatment; (2) age ranged from 40 to 80 years (inclusive); (3) neurological and functional deficits ranged from light to heavy ≤60). MCA cortical and subcortical ischemic infarcts of any size, in line with clinical features were confirmed by CT scanning.